Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial

BACKGROUND AND OBJECTIVE: Trastuzumab is a standard care as adjuvant chemotherapy (AdjCT) for patients with human epidermal growth factor receptor 2 (HER2)-positive primary breast cancer (BC) in Japan. However, no reports have evaluated its economics for patients with HER2-positive BC over 70 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Takumoto, Yuki, Shiroiwa, Takeru, Shimozuma, Kojiro, Iwata, Hiroji, Takahashi, Masato, Baba, Shinichi, Kobayashi, Kokoro, Hagiwara, Yasuhiro, Kawahara, Takuya, Uemura, Yukari, Mukai, Hirofumi, Taira, Naruto, Sawaki, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930935/
https://www.ncbi.nlm.nih.gov/pubmed/35233755
http://dx.doi.org/10.1007/s40261-022-01124-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930935/
https://www.ncbi.nlm.nih.gov/pubmed/35233755
http://dx.doi.org/10.1007/s40261-022-01124-y

Ejemplares similares